Literature DB >> 30911897

Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.

Ran Wang1, Lyu Xie2, Na Gao1, Dongying Fan1, Hui Chen1, Peigang Wang1, Hongning Zhou3, Jing An4,5.   

Abstract

The incidence of Japanese encephalitis (JE) has significantly decreased in China due to JE vaccines. In this study, we investigated the post-JE vaccination seroprevalence and protection provided by vaccinated sera against Japanese encephalitis virus (JEV) to elucidate the persistence and waning of antibodies to JEV among JE-SA14-14-2-vaccinated children. A total of 300 serum samples were collected from vaccinated children aged 3-10 years in Zhaotong, Yunnan, China. The seroprevalence of anti-JEV antibodies was determined by enzyme-linked immune sorbent assay and plaque reduction neutralization test. The highest seropositivity of 82% was observed in vaccinated children during the first 0.5-1.5 years after booster vaccination. Then, the seropositivity began to decline and remained lower than the original level observed in the 0.5-1.5-year group. An association was found between the waning of seroprevalence and elapsed time of the post-booster vaccination. Similarly, the neutralizing antibody (nAb) titres gradually decreased over time, and the levels showed a positive correlation with the protective efficacy in mice. This finding suggests that nAbs play an important role in the antiviral process and that the nAb titre is an adequately credible parameter for evaluating the protective efficacy induced by the JE vaccine. Our results provide data that clarify the persistence and waning of antibodies to JEV, which may help elucidate the pathogenesis of JE.

Entities:  

Keywords:  Japanese encephalitis virus (JEV); Neutralizing antibodies; SA14-14-2; Seroprevalence; Waning of antibody

Mesh:

Substances:

Year:  2019        PMID: 30911897      PMCID: PMC6599503          DOI: 10.1007/s12250-019-00099-z

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  36 in total

1.  Japanese encephalitis.

Authors:  T Solomon; N M Dung; R Kneen; M Gainsborough; D W Vaughn; V T Khanh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

2.  Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study.

Authors:  Heechoul Ohrr; J B Tandan; Young Mo Sohn; Sun Heang Shin; Durga Prasad Pradhan; Scott B Halstead
Journal:  Lancet       Date:  2005 Oct 15-21       Impact factor: 79.321

Review 3.  Overview: Japanese encephalitis.

Authors:  Usha Kant Misra; Jayantee Kalita
Journal:  Prog Neurobiol       Date:  2010-02-02       Impact factor: 11.685

4.  Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program.

Authors:  Eiji Konishi; Yoko Kitai; Yukiko Tabei; Koichi Nishimura; Seiya Harada
Journal:  Vaccine       Date:  2010-01-15       Impact factor: 3.641

5.  A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.

Authors:  Young Mo Sohn; J B Tandan; Sutee Yoksan; Min Ji; Heechoul Ohrr
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

6.  Seroepidemiology study of Japanese encephalitis neutralizing antibodies in southern Taiwan: a comparative study between urban city and country townships.

Authors:  Hung-Fu Tseng; Hsiu-Fen Tan; Chen-Kang Chang; Wei-Lun Huang; Wong-Ching Ho
Journal:  Am J Infect Control       Date:  2003-11       Impact factor: 2.918

Review 7.  Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Authors:  Vandana Saxena; Tapan N Dhole
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

8.  Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice.

Authors:  Eiji Konishi; Naoko Ajiro; Chiyoko Nukuzuma; Peter W Mason; Ichiro Kurane
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

9.  Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine.

Authors:  Chang-Jer Wu; Hui-Wen Huang; Mi-Hua Tao
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004.

Authors:  Joachim Hombach; Tom Solomon; Ichiro Kurane; Julie Jacobson; David Wood
Journal:  Vaccine       Date:  2005-07-18       Impact factor: 3.641

View more
  3 in total

1.  The epidemiology and disease burden of children hospitalized for viral infections within the family Flaviviridae in China: A national cross-sectional study.

Authors:  Ran Wang; Xinyu Wang; Linlin Zhang; Guoshuang Feng; Mengjia Liu; Yueping Zeng; Zhengde Xie
Journal:  PLoS Negl Trop Dis       Date:  2022-07-05

2.  T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine.

Authors:  Ran Wang; Zida Zhen; Lance Turtle; Baohua Hou; Yueqi Li; Na Wu; Na Gao; Dongying Fan; Hui Chen; Jing An
Journal:  Appl Microbiol Biotechnol       Date:  2020-06-15       Impact factor: 4.813

3.  Epidemic Changes and Spatio-Temporal Analysis of Japanese Encephalitis in Shaanxi Province, China, 2005-2018.

Authors:  Shuxuan Song; Hongwu Yao; Zurong Yang; Zhen He; Zhongjun Shao; Kun Liu
Journal:  Front Public Health       Date:  2020-08-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.